Shionogi, Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1919-01-01
- Employees
- -
- Market Cap
- $13.1B
A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-04-12
- Last Posted Date
- 2018-04-24
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 481
- Registration Number
- NCT00459745
- Locations
- 🇺🇸
East-West Medical Research Institute, Honolulu, Hawaii, United States
🇺🇸Welborn Clinic Gateway, Newburgh, Indiana, United States
🇺🇸Memorial Research Medical Clinic, Long Beach, California, United States
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-01-12
- Last Posted Date
- 2013-06-28
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 826
- Registration Number
- NCT00276094
Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-02-26
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 9
- Registration Number
- NCT00078390
- Locations
- 🇺🇸
Lombardi Cancer Center, Washington, District of Columbia, United States
🇺🇸Scripps Cancer Institute, La Jolla, California, United States
🇺🇸University of Kansas Cancer Center, Kansas City, Kansas, United States
A Phase 1 Study of S-3304 in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- First Posted Date
- 2002-04-10
- Last Posted Date
- 2018-04-26
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 32
- Registration Number
- NCT00033215
- Locations
- 🇺🇸
Roswell Park Cancer Center, Buffalo, New York, United States
🇺🇸H. Lee Moffitt Concer Center and Research Institute, Tampa, Florida, United States
🇺🇸Cleveland Clinic Foundation, Cleveland, Ohio, United States
© Copyright 2024. All Rights Reserved by MedPath